双时间点18F-FDG-PET及PET/CT鉴别良恶性肌肉骨骼病变的机会与局限
本文综述同行评议文献,总结标准18F-FDG-PET/CT在肌肉骨骼病变中的假阳性和假阴性结果,讨论双时间点显像(DTPI)和延迟显像在鉴别良恶性肌肉骨骼病变中的附加价值与局限。DTPI的定量和半定量参数主要为最大标准化摄取值(SUVmax)和滞留指数(RI),但各项研究中诊断恶性的标准和截断值差异很大,方案、判读和结果也存在显著异质性。尽管性能报道存在明显矛盾,DTPI在提高判读信心方面仍可能有用,但假阳性和假阴性原因以及良恶性病变摄取模式重叠是主要障碍。
要点
- DTPI定量参数主要为SUVmax和滞留指数RI,但各研究诊断恶性的标准和截断值差异很大。
- 当使用与初始标准单时间点显像相同的诊断标准时,DTP PET因背景活性持续清除和恶性病变18F-FDG积累增加而提高灵敏度。
- 假阳性(如活动性感染或炎症病变及局部侵袭性良性肿瘤)和假阴性(如低级别肉瘤)是降低该技术诊断价值的主要障碍。
核心结论
- DTPI在提高判读信心方面可能仍有用,但假阳性和假阴性原因以及良恶性病变摄取模式重叠是主要障碍。
- 进一步系统研究、采用统一方案和判读标准可能明确DTPI的具体适应证和判读标准,以提高肌肉骨骼病变的诊断准确性。
研究设计与样本
- 本文为综述,基于对同行评议文献的回顾,总结标准18F-FDG-PET/CT在肌肉骨骼病变中的假阳性和假阴性结果,并讨论DTPI和延迟显像的附加价值与局限。
主要发现
- DTPI采用的定量和半定量参数为标准化摄取值(主要为SUVmax)和滞留指数RI,RI(%)=100%×(SUVmax延迟- SUVmax早期)/SUVmax早期。
- 各研究中诊断恶性的标准和截断值差异很大,DTP 18F-FDG-PET在鉴别良恶性肌肉骨骼病变方面的方案(延迟显像时间点)、判读和结果存在显著异质性。
- DTPI的特异性取决于多种因素,如肌肉骨骼病变或恶性肿瘤的性质、患者人群中假阳性病因的患病率以及用于定义恶性的截断值(SUVmax或RI)。
- 当使用与初始标准单时间点显像相同的诊断标准时,DTP PET因背景活性持续清除和恶性病变18F-FDG积累增加而提高18F-FDG-PET/CT的灵敏度。
- 假阳性(如活动性感染或炎症病变及局部侵袭性良性肿瘤)和假阴性(如低级别肉瘤)是降低该技术诊断价值的主要障碍,良恶性肌肉骨骼病变在DTPI上的18F-FDG摄取模式存在重叠。
关键数值与推荐
- 滞留指数RI(%)=100%×(SUVmax延迟- SUVmax早期)/SUVmax早期。
- 各研究中诊断恶性的标准和截断值差异很大;DTPI特异性取决于病变性质、假阳性病因患病率以及所用截断值(SUVmax或RI)。
临床怎么用
- DTPI可能有助于提高判读信心,如鉴别恶性病变与无活动性或慢性炎症部位、治疗后存活残留与坏死以及某些其他良性病变。
- 考虑PET/CT的诊断性CT成分和患者临床情况可提高特定病例判读的特异性。
局限性
- 各研究中诊断恶性的标准和截断值差异很大。
- 各研究在方案(延迟显像时间点)、判读和结果方面存在显著异质性。
- 假阳性(如活动性感染或炎症病变及局部侵袭性良性肿瘤)和假阴性(如低级别肉瘤)是降低该技术诊断价值的主要障碍,良恶性肌肉骨骼病变在DTPI上的18F-FDG摄取模式存在重叠。
- DTPI的性能报道存在明显矛盾。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In this review, we summarize the false-positive and false-negative results of standard 18F-FDG-PET/CT in characterizing musculoskeletal lesions and discussed the added value and limitations of dual-time point imaging (DTPI) and delayed imaging in differentiating malignant from benign musculoskeletal lesions, based on review of the peer-reviewed literature. The quantitative and semiquantitative parameters adopted for DTPI are standardized uptake value (mainly maximum standardized uptake value [SUVmax]) and retention index (RI), calculated as RI (%) = 100% × (SUV [maxD-Delayed] - SUV [maxE-Early])/SUV [maxE-Early], although the criteria and cutoff for diagnosing malignancy in studies have varied considerably. Also, there has been considerable heterogeneity in protocol (time point of delayed imaging), interpretation, and results in dual-time point (DTP) 18F-FDG-PET for differentiating malignant from benign musculoskeletal lesions in various research studies. The specificity of DTPI is a function of many factors such as the nature of the musculoskeletal lesion or malignancy in question, the prevalence of false-positive etiologies in the patient population, and the cutoff values (either SUVmax or RI) employed to define a malignancy. Despite the apparent conflicting reports on the performance, there have been certain common points of agreement regarding DTPI: (1) DTP PET increases the sensitivity of 18F-FDG-PET/CT due to continued clearance of background activity and increasing 18F-FDG accumulation in malignant lesions, when the same diagnostic criteria (as in the initial standard single-time point imaging) are used. Increased sensitivity for lesion detection can be viewed as a strong point of DTP and delayed-time point imaging. (2) The causes for false positives (such as active infectious or inflammatory lesions and locally aggressive benign tumors) and false negatives (eg, low-grade sarcomas) are the major hurdles accounting for reduced diagnostic value of the technique, with overlap of 18F-FDG uptake patterns between benign and malignant musculoskeletal lesions on DTPI. (3) DTPI, however, could still be potentially useful in increasing the confidence of interpretation such as differentiating malignancy from sites of inactive or chronic inflammation, post-treatment viable residue vs necrosis, and certain other benign lesions. (4) Consideration of diagnostic CT component of PET/CT and the patient's clinical picture can lead to increase in specificity of interpretation in a given case scenario. Further systematic research, adoption of uniform protocol, and interpretation criterion could evolve the specific indications and interpretation criteria of DTPI for improved diagnostic accuracy in musculoskeletal lesions and its clinical applications.
引用
- Parghane RV, Basu S. Dual-time point 18F-FDG-PET and PET/CT for Differentiating Benign From Malignant Musculoskeletal Lesions: Opportunities and Limitations. Semin Nucl Med. 2017. PMID: 28583277. doi:10.1053/j.semnuclmed.2017.02.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。